通过PI3K/AKT信号通路,PRKAA2通过PI3K/AKT信号通路调解了与代谢功能障碍相关的脂肪性肝病的发病过程
Jiayi Li1, Guiling Wu1, Zihao Li2
1Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 涉及升高的PRKAA2. 向PRKAA2通过hsa-let-7b-5p/PRKAA2/PI3K/AKT通路减少肝脏脂肪和炎症.
科学领域:
- 肝病学和代谢疾病研究.
- 肝脏疾病的分子机制.
- 在MASLD中发现生物标志物.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是慢性肝病的主要原因.
- 蛋白质激酶AMP激活的催化子单元α2 (PRKAA2) 与代谢调节有关.
- 在MASLD病原体中PRKAA2的特定作用尚不清楚.
研究的目的:
- 为了阐明PRKAA2在MASLD中的分子机制.
- 在MASLD中识别PRKAA2的上游调节器和下游通路.
- 探索PRKAA2作为MASLD的潜在治疗点.
主要方法:
- 对公共数据集的生物信息分析,以确定PRKAA2在MASLD中的作用.
- 在体外和体内实验评估PRKAA2表达和功能的实验.
- 细胞因子和脂类物种的量化,以及PI3K/AKT通路激活的评估.
- 双露西法酶记者测定以确认miRNA-目标相互作用.
主要成果:
- 在MASLD模型中,PRKAA2被显著上调.
- 降低PRKAA2 Knockdown减少了脂质积累和促炎性细胞因子的产生.
- 通过PRKAA2抑制减弱PI3K/AKT通路的酸化.
- 鉴定出hsa-let-7b-5p是PRKAA2.2的直接上游调节剂.
结论:
- PRKAA2是MASLD病变发生的关键调解者.
- 发现了一个新的调节轴,涉及hsa-let-7b-5p,PRKAA2和PI3K/AKT通路.
- PRKAA2代表了MASLD的潜在治疗标.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
The JAK-STAT Signaling Pathway
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Insulin: The Receptor and Signaling Pathways
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
